Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Avalo Therapeutics (AVTX), a clinical stage biotechnology company specializing in immune dysregulation treatments, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Garry A. Neil, CEO and Board Chairman, will deliver a presentation at this virtual event on Tuesday, February 11, 2025, at 10:00 a.m ET.
Interested parties can access both the live webcast and replay through the 'News / Events' section of Avalo's investor relations website at ir.avalotx.com. The presentation recording will remain available for a minimum of 30 days following the event.
Avalo Therapeutics (AVTX), un'azienda biotecnologica in fase clinica specializzata nei trattamenti per la disregolazione immunitaria, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute. Dr. Garry A. Neil, CEO e Presidente del Consiglio, terrà una presentazione durante questo evento virtuale martedì 11 febbraio 2025, alle 10:00 a.m ET.
Le parti interessate possono accedere sia al webcast in diretta che alla registrazione attraverso la sezione 'News / Events' del sito web per le relazioni con gli investitori di Avalo all'indirizzo ir.avalotx.com. La registrazione della presentazione sarà disponibile per un minimo di 30 giorni dopo l'evento.
Avalo Therapeutics (AVTX), una compañía de biotecnología en etapa clínica especializada en tratamientos para la disregulación inmunitaria, ha anunciado su próxima participación en la 35.ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. Dr. Garry A. Neil, CEO y Presidente de la Junta, realizará una presentación en este evento virtual el martes 11 de febrero de 2025, a las 10:00 a.m. ET.
Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición a través de la sección 'News / Events' del sitio web de relaciones con inversores de Avalo en ir.avalotx.com. La grabación de la presentación estará disponible por un mínimo de 30 días después del evento.
Avalo Therapeutics (AVTX)는 면역 불균형 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 옵퍼하이머 제35회 연례 헬스케어 생명과학 Conference에 참가할 예정이라고 발표했습니다. Garry A. Neil 박사, CEO 겸 이사회 의장이 2025년 2월 11일 화요일 오전 10시 ET에 이 가상 행사에서 발표를 진행할 예정입니다.
관심 있는 분들은 Avalo의 투자자 관계 웹사이트 ir.avalotx.com의 '뉴스 / 이벤트' 섹션을 통해 실시간 웹캐스트 및 재생을 이용할 수 있습니다. 발표 녹화는 행사 후 최소 30일 동안 이용 가능합니다.
Avalo Therapeutics (AVTX), une entreprise de biotechnologie en phase clinique spécialisée dans les traitements de dysrégulation immunitaire, a annoncé sa future participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé. Dr. Garry A. Neil, PDG et Président du Conseil, présentera lors de cet événement virtuel le mardi 11 février 2025, à 10h00 ET.
Les parties intéressées peuvent accéder au webcast en direct et à la rediffusion via la section 'News / Events' du site web des relations avec les investisseurs d'Avalo à l'adresse ir.avalotx.com. L'enregistrement de la présentation sera disponible pendant au moins 30 jours après l'événement.
Avalo Therapeutics (AVTX), ein Unternehmen der klinischen Biotechnologie, das sich auf Behandlungen zur Immunfehlregulation spezialisiert hat, hat seine bevorstehende Teilnahme an der 35. jährlichen Oppenheimer Konferenz für Gesundheits- und Lebenswissenschaften angekündigt. Dr. Garry A. Neil, CEO und Vorsitzender des Vorstands, wird am Dienstag, den 11. Februar 2025, um 10:00 Uhr ET eine Präsentation bei dieser virtuellen Veranstaltung halten.
Interessierte können sowohl auf das Live-Webcast als auch auf die Wiederholung über den Bereich 'News / Events' der Investoren-Relations-Website von Avalo unter ir.avalotx.com zugreifen. Die Aufzeichnung der Präsentation wird für mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.
Live webcast and replay can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
When is Avalo Therapeutics (AVTX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch AVTX's Oppenheimer Conference presentation?
How long will AVTX's Oppenheimer Conference presentation replay be available?
Who will be presenting for AVTX at the Oppenheimer Healthcare Conference?
What is the focus area of Avalo Therapeutics (AVTX)?
